Predictive Accuracy of Cell Death Assays
IN GYN TUMOR TYPES
The following data compilation of 345 patients
from 11 peer reviewed published articles in ovarian tumors
establish the positive predictive accuracy of cell death assays
at 77.0% and negative predictive accuracies of 87.9%. This
breakdown reveals compelling evidence that assay directed
therapies could improve response rates, time to progression
and survival.
| Author |
N |
TP |
TN |
FP |
FN |
Ref # |
Positive Predictive
Accuracy |
Negative Predictive Accuracy |
False Positive % |
False Negative % |
| Blackman |
72 |
31 |
27 |
13 |
1 |
1 |
70.5% |
96.4% |
18.1% |
1.4% |
| Carstensen |
22 |
6 |
12 |
4 |
0 |
2 |
60.0% |
100.0% |
18.2% |
0.0% |
| Ng |
20 |
3 |
14 |
3 |
0 |
3 |
50.0% |
100.0% |
15.0% |
0.0% |
| Konecny |
38 |
19 |
8 |
10 |
1 |
4 |
65.5% |
88.9% |
26.3% |
2.6% |
| Ohie |
15 |
7 |
6 |
1 |
1 |
5 |
87.5% |
85.7% |
6.7% |
6.7% |
| Sargent |
25 |
9 |
9 |
6 |
1 |
6 |
60.0% |
90.0% |
24.0% |
4.0% |
| Sevin |
31 |
23 |
6 |
0 |
2 |
7 |
100.0% |
75.0% |
0.0% |
6.5% |
| Sevin |
65 |
45 |
12 |
3 |
5 |
8 |
93.8% |
70.6% |
4.6% |
7.7% |
| Taylor |
37 |
11 |
17 |
6 |
3 |
9 |
64.7% |
85.0% |
16.2% |
8.1% |
| Weisenthal |
3 |
1 |
2 |
0 |
0 |
10 |
100.0% |
100.0% |
0.0% |
0.0% |
| Nagourney |
17 |
9 |
3 |
3 |
2 |
11 |
75.0% |
60.0% |
17.6% |
11.8% |
| |
|
|
|
|
|
|
|
|
|
|
| TOTAL |
345 |
164 |
116 |
49 |
16 |
|
77.0% |
87.9% |
14.2% |
4.6% |
- 1. Blackman KE,
Fignert HJ, Fuller AF, Meitner PA. The Fluorescent Cytoprint
Assay in gynecologic malignancies and breast cancer: methodology
and results. In: Koechli OR, Sevin B-U, Haller U, eds. Chemosensitivity
testing in gynecologic malignancies and breast cancer. Basel:
Karger, 1994: 53-64.
- 2. Carstensen H, Tholander B. Chemosensitivity of ovarian
carcinoma: In vitro/in vivo correlations using the dye exclusion
assay of Weisenthal (meeting abstract). Proceedings: 3rd European
Conference on Clinical Oncology 1985; Stockholm: p. 206.
- 3. Ng TY, Ngan HYS, Cheng DKL, Wong LC. Clinical applicability
of the ATP cell viability assay as a predictor of chemoresponse
in platinum-resistant epithelial ovarian cancer using nonsurgical
tumor cell samples. Gynec Oncol 2000; 76: 405-408.
- 4. Konecny G, Crohns C, Pegram M, et al. Correlation of drug
response with the ATP tumor chemosensitivity assay in primary
FIGO stage III ovarian cancer. Gynec Oncol 2000; 77: 258-263.
- 5. Ohie S. Udagawa Y, Kozu A, et al. Cisplatin sensitivity
of ovarian cancer in the histoculture drug response assay
correlates to clinical response to combination chemotherapy
with Cisplatin, Doxorubicin and Cyclophosphamide. Anticancer
Res 2000; 20: 2049-2054.
- 6. Sargent J, Elgie A, Taylor CG, Wilson J, Alton P, Hill
JG. The identification of drug resistance in ovarian cancer
and breast cancer; application of the MTT assay. In: Koechli
OR, Sevin B-U, Haller U, eds. Chemosensitivity testing in
gynecologic malignancies and breast cancer. Basel: Karger,
1994: 64-75.
- 7. Sevin B-U, Perras JP, Averette HE, Donato DM, Penalver
M. Chemosensitivity testing in ovarian cancer. Cancer 1993;
71(Suppl): 1613-1620.
- 8. Sevin B-U, Perras JP, Koechli OR. Current status and future
directions of chemosensitivity testing. In: Koechli OR, Sevin
B-U, Haller U, eds. Chemosensitivity testing in gynecologic
malignancies and breast cancer. Basel: Karger, 1994: 179-194.
- 9. Taylor CG, Sargent JM, Elgie AW, et al. The clinical relevance
of chemosensitivity testing in ovarian cancer. Cancer Detect
Prev 1998; 22: 305-312.
- 10. Weisenthal LM, Marsden JA, Dill PL. Macaluso CK. A novel
dye exclusion method for testing in vitro chemosensitivity
of human tumors. Cancer Res 1983; 43: 749-757.
- 11. Nagourney RA, Brewer CA, Radecki S, et al. A Phase II
Trial of Gemcitanbine Plus Cisplatin Repeating Doublet Therapy
in Previously Treated, Relapsed Ovarian Cancer patients. Submitted
Gyn Onc May 2002.
|